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PANEL: RESEARCH IN CONTEXT 1 
Evidence before this study 2 
Results from a phase 2a trial (NCT00264888) showed that ataluren improved dystrophin 3 
expression in the skeletal muscle of patients with nonsense mutation Duchenne muscular 4 
dystrophy (nmDMD) after 28 days of treatment. Results from the 6-minute walk test (6MWT) 5 
and other timed function tests (TFTs) from a 48-week, phase 2b trial (NCT00592553) 6 
showed a clinical benefit of ataluren (at a dose of 40 mg/kg/day) versus placebo in patients 7 
with nmDMD. In this phase 2b trial, a post-hoc, subgroup analysis showed that the treatment 8 
effect was more evident in patients predicted to be in the decline phase of disease (i.e. those 9 
aged 7−16 years with a baseline 6-minute walk distance [6MWD] ≥150 m and ≤80%-10 
predicted for age and height). Furthermore, recent natural history studies have shown that 11 
patients with a baseline 6MWD >400 m show fewer declines across multiple measures of 12 
physical function. In contrast, patients with a baseline 6MWD <300 m are at higher risk of 13 
precipitous declines in 6MWD and loss of ambulation in the subsequent year. 14 
Added value of this study 15 
In the present phase 3 trial (NCT01826487), ataluren-treated boys (aged 7−16 years) in the 16 
intent-to-treat (ITT) population showed a 13·0-m least square (LS) mean difference, 17 
(standard error of the mean, SEM=10·4); p=0·213 (observed difference, 15·4 m), 18 
numerically favouring ataluren, in 6MWD after 48 weeks of treatment compared with 19 
placebo-treated boys. In addition, treatment with ataluren led to a statistically significant 20 
42·9-m LS mean difference (15·9); p=0·007 (observed difference, 47·2 m) in 6MWD versus 21 
placebo in a pre-specified subgroup of patients with nmDMD in the mid-range (declining) 22 
stage of disease who had a baseline 6MWD ≥300 m to <400 m; a subgroup of patients in 23 
whom a treatment response, as measured by the 6MWT, is more likely to be observed over 24 
48 weeks. This is owing to the limited sensitivity of the 6MWT (over a 48-week study) in 25 
patients with higher baseline function (defined as stable, baseline 6MWD ≥400 m), and 26 
because of the increased interpatient variability seen in patients with lower baseline 27 
ambulatory function (those at risk of loss of ambulation, baseline 6MWD <300 m). Ataluren-28 
 4 
 
treated patients in the ITT population showed less deterioration numerically, as measured by 29 
the TFTs, versus placebo; this treatment effect was more evident in patients with a baseline 30 
6MWD ≥300 to <400 m. Ataluren-treated patients in the ≥300 to <400 m subgroup also 31 
experienced benefits in function versus placebo, as measured by the North Star Ambulatory 32 
Assessment (NSAA). Furthermore, a post-hoc analysis using data from the NSAA showed 33 
that patients in the ITT population and in the subgroup with baseline 6MWD ≥300 to <400 m 34 
experienced statistically significant reductions in the relative risk of loss of clinically 35 
meaningful milestones versus placebo (31% and 46% reduction, respectively; both 36 
p=0·010).   37 
Implications of all the available evidence 38 
These results demonstrate the clinical benefit of ataluren in a subgroup of patients with 39 
nmDMD with a baseline 6MWD ≥300 to <400 m, in whom the 6MWT is most likely to show a 40 
treatment benefit over a 48-week trial, owing to the increased sensitivity of this outcome 41 




Background This trial examined the efficacy and safety of ataluren in ambulatory boys with 44 
nonsense mutation Duchenne muscular dystrophy (nmDMD).  45 
Methods This 48-week, phase 3, multicentre, randomised, double-blind, placebo-controlled 46 
trial was conducted across 54 sites (18 countries). Key inclusion criteria: nmDMD; boys aged 47 
7−16 years; and baseline 6-minute walk distance (6MWD) ≥150 m and ≤80%-predicted for 48 
age and height. Patients were randomised (1:1) to receive ataluren orally thrice daily (40 49 
mg/kg/day) or placebo. The primary endpoint was change in 6MWD from baseline in the 50 
intent-to-treat (ITT) population. A pre-specified subgroup of patients with a baseline 6MWD 51 
≥300 to <400 m was also assessed. Secondary endpoints included timed function tests 52 
(TFTs). ClinicalTrials.gov: NCT01826487 (completed).   53 
Findings Patients were recruited (Mar 26, 2013–Aug 26, 2014), and randomised to receive 54 
ataluren (n=115) or placebo (n=115). The decrease in 6MWD after 48 weeks was less with 55 
ataluren (n=114) than with placebo (n=114): least square (LS) mean (standard error of 56 
mean, SEM) ataluren vs placebo, ITT: 13·0 (10·4) m; p=0·213; ≥300 to <400 m subgroup: 57 
42·9 (15·9) m; p=0·007. Ataluren-treated patients experienced less of a decline versus 58 
placebo for TFTs (LS mean ataluren vs placebo, ITT: 10-m run/walk: −1·1 s, p=0·117; 4-59 
stair climb: −1·4 s, p=0·058, 4-stair descend: −2·0 s, p=0·012); this was more evident in the 60 
≥300 to <400 m subgroup. Ataluren was generally well tolerated (treatment-related adverse 61 
events: ataluren, 33·9% [39/115]; placebo, 20·9% [24/115]); most were mild to moderate in 62 
severity. 63 
Interpretation Ataluren-treated ITT patients did not experience a statistically-significant 64 
change in 6MWD versus placebo over 48 weeks, although significant effects on other 65 
measures were observed. Change in 6MWD was statistically significant in the pre-specified 66 
≥300 to <400 m subgroup; in whom a consistent treatment response is more likely to be 67 
observed over a 48-week period using this measure.  68 
Funding PTC Therapeutics, Inc. 69 
  
†Baseline 6MWD values for two patients (placebo, n=1; ataluren 80 mg/kg/day, n=1) were lower than their screening values, 
owing to lower limb injuries that occurred before the baseline visit. These values were therefore replaced with the patients’ 
screening values; this population is therefore referred to as the corrected intent-to-treat population. 
                                                                                                                                                                                   6 
INTRODUCTION 70 
Duchenne muscular dystrophy (DMD) is a severe, progressive and rare neuromuscular, X-71 
linked recessive disease.1 Corticosteroids and better coordinated care have improved 72 
outcomes in DMD in the past several decades,2,3 but these approaches do not specifically 73 
target dystrophin deficiency, which is the underlying cause of DMD.4 Mutation-specific 74 
therapies, aimed at restoring dystrophin protein production, are therefore being explored. 75 
Ataluren promotes readthrough of nonsense mutations to produce full-length functional 76 
dystrophin protein.4-7 Approximately 10–15% of patients with DMD have a nonsense 77 
mutation,8 which introduces a premature stop codon into the dystrophin mRNA, leading to 78 
the translation of a truncated, non-functional protein. The readthrough mechanism of 79 
ataluren targets this mutation to treat the underlying cause of disease.4  80 
 81 
Results from a phase 2a, open-label, dose-ranging, 28-day trial (NCT00264888) 82 
demonstrated an increase from baseline in the dystrophin/spectrin expression ratio in 61% 83 
(23/38) of patients with nonsense mutation DMD (nmDMD) after 28 days of treatment with 84 
ataluren (16, 40, or 80 mg/kg/day).6 A phase 2b, randomised, double-blind, placebo-85 
controlled trial (NCT00592553) showed a slowing of disease progression in patients 86 
receiving ataluren (40 mg/kg/day) versus placebo, as measured by a change in their 6-87 
minute walk distance (6MWD) after 48 weeks (corrected intent-to-treat†: observed mean 88 
difference=31·3 m;7 least square [LS] mean difference=31·7 m; nominal p=0·0197; adjusted 89 
p=0·0367);9 but failed to achieve its primary endpoint. However, secondary outcome 90 
measures, including timed function tests (TFTs), supported these results and consistently 91 
favoured ataluren over placebo.7,9 In a subgroup of patients who were in ambulatory decline 92 
(7−16 years old, with a baseline 6MWD ≥150 m and ≤80%-predicted for age and height), the 93 
observed mean difference in 6MWD between ataluren- and94 
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placebo-treated patients was 49·9 m7,9,10 (LS mean difference=45·6 m, nominal p=0·0096;  95 
adjusted p=0·0182; PTC Therapeutics, data on file).  96 
 97 
The 6-minute walk test (6MWT) and TFTs are recommended in guidelines by the European 98 
Medicines Agency13 and the US Food and Drug Administration for use in clinical trials of 99 
DMD.14 These guidelines recommend stratifying patients according to disease status, 100 
functional status and/or developmental stage.13,14 Natural history data have shown that 101 
patients  with a baseline 6MWD >400 m show fewer declines in physical functioning than 102 
those with a 6MWD 400 m.15,17,18 In addition, emerging magnetic resonance imaging data 103 
have shown that, as DMD progresses, fibrotic tissue and fat replace muscle fibres,19 104 
contributing to a patient’s physical decline. Magnetic resonance spectroscopy data have 105 
shown that patients with >80% fat fraction in the vastus lateralis muscle are likely to have a 106 
6MWD <300 m and are at increased risk of losing ambulation compared with those with a 107 
6MWD ≥300 m.20 Treatment effects using the 6MWT are therefore more likely to be 108 
observed in patients in the mid-range (declining) stage of disease (baseline 6MWD ≥300 to 109 
<400 m). This is owing to the limited sensitivity of the 6MWT (over 48 weeks) for patients 110 
with higher baseline function (defined as stable, 6MWD >400 m), and to the increased 111 
interpatient variability seen in patients with lower baseline ambulatory function (those at risk 112 
of loss of ambulation, 6MWD <300 m).  113 
 114 
The aim of this phase 3 trial (ACT DMD, Ataluren Confirmatory Trial of Patients with 115 
nmDMD) was to evaluate the ability of ataluren to stabilise ambulation, as measured by the 116 
6MWT, in patients with nmDMD in ambulatory decline compared with placebo over 48 117 
weeks, and to determine the effect of ataluren on other measures of physical function. 118 
Based on an evolving understanding of the 6MWT,15,16 a pre-specified analysis of patients 119 





Study design 123 
This was a phase 3, multicentre, randomised, double-blind, placebo-controlled trial 124 
evaluating the efficacy and safety of ataluren orally three times daily in ambulatory boys with 125 
nmDMD (NCT01826487). The trial comprised a 2-week screening period, followed by a 48-126 
week blinded treatment period, in which patients received either ataluren or placebo. 127 
Subsequently, patients were eligible to enter an open-label extension (NCT02090959). 128 
Assessments were performed during screening, at baseline, and then every 8 weeks until 129 
the end of treatment. The study was conducted at 54 sites in 18 countries (Australia, 130 
Belgium, Brazil, Canada, Chile, Czech Republic, France, Germany, Israel, Italy, Poland, 131 
South Korea, Spain, Sweden, Switzerland, Turkey, UK, and the USA). The trial and any 132 
changes to the protocol were approved by the local regulatory authorities and the 133 
institutional review board of each site. The trial was conducted in accordance with the 134 
Declaration of Helsinki (2000) and the ethical principles of Good Clinical Practice, according 135 
to the International Conference on Harmonisation Harmonised Tripartite Guideline.  136 
 137 
Patients 138 
Patients who met the following inclusion criteria were eligible for enrolment: boys aged 7−16 139 
years; phenotypic evidence of dystrophinopathy (onset of characteristic clinical symptoms or 140 
signs by 6 years of age, elevated serum creatine kinase levels and difficulty with 141 
ambulation); nmDMD, confirmed by gene sequencing; use of systemic corticosteroids for at 142 
least 6 months before the start of treatment, with no significant change in dosage/dosing 143 
regimen (not related to change in body weight) for at least 3 months before the start of 144 
treatment and an expectation that this would not change during the study; and a 6MWD 145 
≥150 m and ≤80%-predicted for age and height during screening. Subsequently, patients 146 
were required to perform two valid 6MWTs on 2 separate days (with the second value 20% 147 
of the first value). The mean of these two performances was taken as the baseline 6MWD, 148 
and was to be within 20% of the screening 6MWD. Patients’ laboratory results during 149 
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screening were required to be within normal ranges (with the exception of tests indicative of 150 
muscle breakdown). Key exclusion criteria included: treatment with systemic aminoglycoside 151 
antibiotics within 3 months of the start of treatment; initiation of systemic corticosteroids in 152 
the 6 months before the start of treatment; and change in systemic corticosteroid therapy 153 
within 3 months before the start of treatment (not related to change in body weight). A full list 154 
of exclusion criteria is provided in the Supplementary Methods. Written, informed consent 155 
was obtained from each patient’s parents or guardians and assent was provided by the 156 
patient (where appropriate). 157 
 158 
Randomisation and masking 159 
Eligible patients were stratified based on age (<9 years and ≥9 years), duration of prior 160 
corticosteroid use (6 to <12 months and ≥12 months), and baseline 6MWD (<350 m and 161 
≥350 m). Patients were randomised 1:1 to receive placebo or ataluren, using the permuted 162 
block randomisation technique, which allowed for the treatment arms to be balanced with 163 
respect to the stratification factors and patient numbers. A study site representative provided 164 
patient information to the interactive voice response/interactive web response system, which 165 
then assigned patients to their treatment arms. Patients, parents/caregivers, investigational 166 
site personnel, PTC Therapeutics employees, and all other study personnel remained 167 
blinded until every patient had completed the study and the database was locked. The 168 
identity of the study treatment was concealed using a placebo that was identical to the active 169 
drug in appearance, taste, odour, packaging and labelling. 170 
 171 
Procedures 172 
Patients received either placebo or ataluren (PTC Therapeutics International Limited, 173 
Ireland) dosed orally three times daily (10, 10 and 20 mg/kg of body weight for morning, 174 
midday, and evening doses) for 48 weeks. Doses were to be given 6 h apart on the same 175 
day, with a 12-h interval between evening and morning doses on the next day. Patients’ 176 
clinical and medical histories were recorded during screening. Vital signs, height, and weight 177 
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measurements, and concomitant medications were recorded, and laboratory assessments 178 
were performed during screening, at baseline, and every 8 weeks until the end of treatment. 179 
A physical examination was performed during screening, at baseline, at 24 weeks, and at 180 
the end of treatment. Additionally, patients’ physical function was assessed using the 181 
6MWT,16,23 TFTs,23 and the North Star Ambulatory Assessment (NSAA)24  during screening, 182 
at baseline, and every 8 weeks until the end of treatment. A second 6MWT was performed at 183 
baseline and at week 48, and the average of the two was used from these visits. 184 
 185 
Outcomes 186 
The primary efficacy endpoint was to determine the ability of ataluren to slow disease 187 
progression in patients in ambulatory decline, as assessed by the 6MWT. The secondary 188 
efficacy endpoint was to determine the effect of ataluren on proximal muscle function, as 189 
assessed by TFTs (10-m run/walk, 4-stair climb, 4-stair descend). The following exploratory 190 
efficacy endpoints were also examined: change in physical function, as assessed by the 191 
percentage of patients who lost ambulation, and by the NSAA (total score);24 parent-reported 192 
health-related quality of life (HRQoL), as assessed by the Pediatric Outcomes Data 193 
Collection Instrument (PODCI); and the activities of daily living (ADL)/disease status survey. 194 
Endpoints were also evaluated in a pre-specified subgroup of patients who had a baseline 195 
6MWD ≥300 to <400 m. Post-hoc analyses included the following: a sensitivity analysis for 196 
the 6MWT, including intervals of baseline distance, a composite TFT endpoint (linear 197 
combination of 10-m run/walk, 4-stair climb and 4-stair descend), the time to loss of ability to 198 
perform the 4-stair climb and 4-stair descend, and the percentage of patients who lost 199 
function across each of the individual 17 items in the NSAA. Lastly, a pre-specified meta-200 
analysis was performed using data from the intent-to-treat (ITT) population of this trial and a 201 
subgroup of patients from the ITT population of the phase 2b trial7 (who met the ACT DMD 202 
entry criteria). Full details for PODCI, ADL and post-hoc analyses are presented in the 203 




Adverse events (AEs) were captured throughout the 48-week treatment period.  206 
 207 
Statistical analyses 208 
Patient populations 209 
The as-treated population comprised all randomised patients who received any study 210 
treatment, with treatment assignments designated according to actual study treatment 211 
received. This population was used to analyse safety and treatment administration. The ITT 212 
population comprised all patients who were randomised, with study drug assignment 213 
designated according to initial randomisation. Patients in this population were required to 214 
have a valid baseline 6MWD value and at least one valid post-baseline 6MWD value. This 215 
population was used to analyse all efficacy parameters. Both the ITT population and the 216 
≥300 to <400 m subgroup were pre-specified in the statistical analysis plan. 217 
 218 
Hypothesis and statistical power 219 
The study hypothesis was that there would be a difference of at least 30 m in change from 220 
baseline to week 48 between ataluren- and placebo-treated patients in the decline phase of 221 
disease. In the phase 2b study, the standard deviation (SD) of the change in observed 222 
6MWD from baseline to week 48 was 72 m in patients receiving ataluren 40 mg/kg/day.7 223 
With 1:1 randomisation, 210 patients would be required (ataluren, n=105; placebo, n=105) to 224 
detect a difference of 30 m in 6MWD with at least 85% power (α=0·05). Assuming that ~5% 225 
of patients discontinue prematurely, a total of 220 patients (ataluren, n=110; placebo, n=110) 226 
would need to be enrolled.  227 
 228 
Statistical analysis of primary and secondary endpoints 229 
The primary analysis of this study evaluated change in 6MWD from baseline to week 48 in 230 
the ITT population using an analysis of covariance (ANCOVA) model. This model included 231 
treatment group and the stratification factors for age, duration of corticosteroid use at 232 
baseline, and baseline 6MWD category, as well as baseline 6MWD as a covariate. If 233 
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patients were unable to perform the 6MWT due to disease progression, a value of zero was 234 
used. Within-treatment group multiple imputations on the actual scale were applied to handle 235 
missing values via the Markov chain Monte Carlo method; 100 imputations were conducted, 236 
which was expected to be adequate given the anticipated amount of missing data. The 237 
MIANALYZE procedure (SAS® software, Version 9.3, [2011], SAS Institute Inc., Cary, NC, 238 
USA) combined the results from the respective invocations of multiple imputations, 239 
producing a final estimate of treatment effect and corresponding standard error.  240 
 241 
The secondary efficacy endpoints were evaluated in a similar manner to the primary 242 
endpoint; however, if the time taken to perform a TFT exceeded 30 s or if a patient could not 243 
perform the test owing to disease progression, a value of 30 s was used. A post-hoc 244 
composite TFT endpoint and the time to loss of ability to perform the 4-stair climb and 4-stair 245 
descend were also analysed (Supplementary Methods). The change in a range of 246 
functions was also measured using the NSAA; a validated, internationally-used tool for 247 
examining treatment effect in patients with DMD.25 For the NSAA,26 patients were rated on a 248 
scale of 0−2 for each of the 17 items by the study investigator. A score of 0 indicated that the 249 
patient was unable to perform the function, a score of 1 indicated that the patient performed 250 
the function with difficulty (independent of physical assistance from another person using a 251 
modified method), and a score of 2 indicated that the patient performed the function (without 252 
modification/assistance). The sum of the 17 activity scores was used to form an ordinal total 253 
score (max score=34). If 13−16 functions were performed, the total score was calculated as 254 
follows: ([sum of the scores] × [17/number of activities completed]). If fewer than 13 activities 255 
were performed, the total score was considered missing. Ordinal scores were transformed to 256 
a linear total score (0−100) for further analysis.27 A post-hoc analysis of loss of individual 257 
functions on the NSAA was also carried out by examining the percentage of patients who 258 
shifted from a score of 1−2 at baseline to a score of 0 after 48 weeks of treatment. A p value 259 
was obtained using  a permutation test with 1000 permutations of treatment assignments 260 
within the original eight strata combinations to account for the correlation between the 17 261 
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items on the NSAA. Details for the PODCI and ADL/disease status survey are included in 262 
the Supplementary Methods. No adjustment for multiple comparisons with respect to 263 
subgroups was made;28 all p values for this study can be considered nominal. 264 
 265 
Professors C M McDonald and E Mercuri had full access to all study data and were 266 






RESULTS  271 
Patients were recruited between Mar 26, 2013 and Aug 26, 2014. Of 291 screened patients, 272 
230 were enrolled and randomised to receive either ataluren (n=115) or placebo (n=115). A 273 
total of 228 patients (ataluren, n=114; placebo, n=114) met the eligibility criteria for inclusion 274 
in the ITT population (Figure 1). Overall, 4% of patients (n=9) discontinued the study 275 
(ataluren, n=5; placebo, n=4). Two patients from the as-treated population (one from each 276 
treatment arm) were prematurely discontinued from the study when dystrophin gene 277 
sequencing did not confirm the presence of a nonsense mutation in the dystrophin gene. In 278 
addition, two patients discontinued (one in each treatment arm) owing to AEs; these were 279 
constipation, possibly related to the study drug (ataluren, n=1) and disease progression 280 
(placebo, n=1). Patient demographics and type of concomitant corticosteroid usage are 281 
shown in Table 1, and were similar at baseline for both treatment arms.  282 
 283 
For the primary efficacy endpoint, the LS mean change (standard error of the mean, SEM) in 284 
6MWD from baseline to 48 weeks in the ITT population was −47·7 (9·3) m for ataluren- and 285 
−60·7 (9·3) m for placebo-treated patients. This resulted in a 13·0 (10·4) m difference 286 
(p=0·213) favouring ataluren (Figure 2A). The observed difference was 15·4 m. This effect 287 
was more evident in the pre-specified subgroup of patients with a baseline 6MWD ≥300 to 288 
<400 m; the LS mean change (SEM) in 6MWD from baseline to 48 weeks was −27·0 (12·6) 289 
m in ataluren-treated patients and −69·9 (12·1) m in placebo-treated patients. This resulted 290 
in a 42·9 (15·9) m difference (p=0·007), favouring ataluren (Figure 2B). The observed 291 
difference was 47·2 m. A post-hoc sensitivity analysis was also performed to assess the 292 
change in 6MWD from baseline in other patient subgroups. The largest change from 293 
baseline in difference between ataluren- and placebo-treated patients was for the pre-294 
specified ≥300 to <400 m subgroup (Supplementary Table 1). In addition, loss of 295 
ambulation was reduced in ataluren- versus placebo-treated patients; overall, 8% (9/114) of 296 
ataluren-treated patients lost ambulation (unable to perform the 6MWT) compared with 12% 297 
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(14/114) of placebo-treated patients. The majority of these patients had severely impaired 298 
ambulation at baseline (6MWD <300 m). For those with a baseline 6MWD ≥300 to <400 m, 299 
no ataluren-treated patient (0/47) lost ambulation versus 8% (4/52) of placebo-treated 300 
patients after 48 weeks of treatment (Supplementary Table 2).   301 
 302 
The TFTs were key secondary efficacy endpoints. In the ITT population, ataluren-treated 303 
patients experienced less of a decline than placebo-treated patients, as measured by the 304 
TFTs, after 48 weeks of treatment (LS mean difference, ataluren vs  placebo [SEM], 10-m 305 
run/walk: −1·1 [0·7] s, p=0·117; 4-stair climb: −1·4 [0·8] s, p=0·058; 4-stair descend: −2·0 306 
[0·8] s, p=0·012; Table 2). However, only the 4-stair descend was statistically significant. 307 
This treatment effect favouring ataluren was more evident in the subgroup of patients with a 308 
baseline 6MWD ≥300 to <400 m (10-m run/walk: −1·8 [1·0] s, p=0·066; 4-stair climb: −3·5 309 
[1·2] s, p=0·003; 4-stair descend: −4·4 [1·2] s, p<0·001; Table 2). A post-hoc composite TFT 310 
analysis was performed (10-m run/walk, 4-stair climb and 4-stair descend), and showed that 311 
patients receiving ataluren exhibited less deterioration than those receiving placebo. This 312 
endpoint showed a statistically significant difference (SEM) of −1·6 (0·7) s between ataluren- 313 
and placebo-treated patients, favouring ataluren (p=0·023; Supplementary Figure 1A). This 314 
effect was more evident in patients with a baseline 6MWD ≥300 to <400 m (−3·5 [1·0] s, 315 
p<0·001; Supplementary Figure 1B). The time to loss of ability to perform the 4-stair climb 316 
and 4-stair descend also favoured ataluren- versus placebo-treated patients 317 
(Supplementary Figures 2A and 2B).  318 
 319 
In the ITT population, a positive LS mean treatment difference (SEM) of 0·8 (0·5) points 320 
(p=0·128) (ordinal scale) was observed in the pre-specified total NSAA score numerically 321 
favouring ataluren-treated patients. In the linear transformed score, there was a 1.5-point 322 
advantage (1·4) for ataluren-treated patients versus placebo (p=0·268). This treatment effect 323 
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was more evident in individuals with a baseline 6MWD ≥300 to <400 m, based on observed 324 
total score (LS mean difference [SEM], 1·7 points [0·8]; p=0·037) and linear transformed 325 
score (4.3-point advantage [2·1] favouring ataluren, p=0·041). A post-hoc analysis to assess 326 
the loss of ability to perform each of the 17 individual items of the NSAA was also performed. 327 
The proportion of ataluren- and placebo-treated patients able to perform each function at 328 
baseline was balanced (Supplementary Table 3). Every patient (ataluren, n=114; placebo, 329 
n=114) performed each of the 17 functions (totalling 1938 total functions per treatment arm). 330 
Ataluren- and placebo-treated patients had 273/1938 and 282/1938 functions assessed as 331 
“0” (inability to perform the activity) at baseline, respectively. In the ITT population, after 48 332 
weeks of treatment, ataluren-treated patients lost 12% (203/1665) of functions compared 333 
with 18% (294/1656) of functions lost by placebo-treated patients from baseline. This 334 
equates to a 31% reduced risk of loss of function for ataluren-treated patients versus those 335 
receiving placebo (p=0·010; Figure 3). This observation was more evident in patients with a 336 
baseline 6MWD ≥300 to <400 m (reduced risk=46%, p=0·010). Results from the PODCI and 337 
ADL/disease status survey also favoured ataluren over placebo (Supplementary Figure 3 338 
and Supplementary Figure 4, respectively). 339 
 340 
To assess the totality of data collected from this phase 3 trial and the earlier phase 2b trial,7 341 
a pre-specified meta-analysis was performed. This analysis showed that when 6MWD data 342 
for the ITT populations from both trials were combined, a 20·0-m (SEM, 8·2) treatment 343 
benefit was observed for ataluren- versus placebo-treated patients over 48 weeks 344 
(Supplementary Figure 5A). Similarly, when TFT data for the ITT population from both 345 
trials were combined, ataluren-treated patients experienced less of a decline than placebo-346 
treated patients (∆ataluren vs placebo [SEM], −1·3 to −1·9 [0·6–0·7] s) (Supplementary 347 




The mean (SD) duration of drug exposure for ataluren- and placebo-treated patients was 350 
332·3 (39·6) and 333·3 (39·7) days, respectively. Ataluren was generally well tolerated, with 351 
a high compliance with the dosing regimen. At least one treatment-emergent AE (TEAE) was 352 
reported for most patients (ataluren vs placebo: 89·6% [103/115] vs 87·8% [101/115]) and 353 
the majority of reported TEAEs were mild to moderate in severity. Treatment-related 354 
(possible or probable) AEs were slightly higher in ataluren- versus placebo-treated patients 355 
(33·9% [39/115] vs 20·9% [24/115]) (Table 3). Severe TEAEs are summarised in 356 
Supplementary Table 4. Serious AEs (SAEs) were reported in eight patients (ataluren, n=4; 357 
placebo, n=4); four of these patients reported more than one serious AE. All reported SAEs, 358 
except one in the placebo group, were considered to be unrelated to treatment. The SAE 359 
that occurred in a placebo-treated patient was abnormal hepatic function possibly related to 360 
treatment. No new safety signals were identified during the course of this 48-week trial. 361 
Additional safety information is reported in the Supplementary Material.  362 




Dystrophin is a structural protein necessary for preserving the integrity of muscle fibres.4 365 
Treatments focusing on dystrophin restoration, such as ataluren, are expected to preserve 366 
existing muscle function, thereby stabilising or slowing disease progression in patients with 367 
DMD. The slowing of disease progression and motor decline is viewed by the DMD 368 
physician community as a realistic expectation for the effect of dystrophin restoration 369 
therapies,29 and patients and their caregivers consider this to be a highly valuable benefit of 370 
therapy.30 Data from this phase 3 trial show a positive safety profile for ataluren and 371 
demonstrate the clinical efficacy of ataluren (40 mg/kg/day) versus placebo in ambulatory 372 
patients with nmDMD in stabilising/slowing disease progression over 48 weeks. Together, 373 
these findings show a favourable risk−benefit profile for ataluren, despite this trial not 374 
meeting its primary endpoint. For the ITT population, the change in 6MWD between 375 
ataluren- and placebo-treated patients was 13·0 m (15·4 m, observed), favouring ataluren. 376 
While this primary endpoint did not reach statistical significance (p=0·213), the treatment 377 
effect in patients with a baseline 6MWD ≥300 to <400 m was more evident (42·9 m, 378 
p=0·007; 47·2 m, observed). Stratifying patients by baseline function is advisable, because 379 
of the decreased sensitivity of the 6MWT in patients with higher baseline function and the 380 
increased interpatient variability in patients with a baseline 6MWD <300 m (PTC 381 
Therapeutics, data on file). It is important to note that a change in 6MWD of <30 m, may be 382 
clinically meaningful from the view point of patients’ self-reported abilities and HRQoL.31  383 
 384 
Additionally, fewer ataluren-treated patients lost ambulation compared with those who 385 
received placebo over 48 weeks, in both the ITT population and in patients with a baseline 386 
6MWD ≥300 to <400 m. Furthermore, a pre-specified meta-analysis of 6MWD and TFT data 387 
from the phase 2b trial7 and this phase 3 trial showed a statistically significant treatment 388 




The TFTs are key secondary endpoints that are predictive of loss of function, including 391 
ambulation.16 Across the TFTs, a 1·1−2·0 s-benefit in ataluren-treated patients versus 392 
placebo in the ITT population was observed after 48 weeks. This treatment effect was more 393 
evident in patients with a baseline 6MWD ≥300 to <400 m (1·8−4·4 s). These findings are 394 
similar to those from a recent one-year DMD trial of prednisone, in which a 1·7-s benefit and 395 
a 1·6-s benefit were observed for prednisone- versus placebo-treated patients when 396 
performing the 10-m run/walk and the 4-stair climb, respectively.32 When examining the 397 
composite TFT endpoint, a statistically significant treatment effect of ataluren versus placebo 398 
was observed.  399 
 400 
The clinical benefit of ataluren was also supported using the NSAA, a DMD-specific 401 
exploratory efficacy endpoint that provides information on a wide spectrum of functions that 402 
are important in everyday life.17 For the total observed and linear transformed NSAA scores, 403 
ataluren-treated ITT patients with a baseline 6MWD ≥300 to <400 m experienced a 404 
statistically significant benefit versus placebo over 48 weeks. Furthermore, a post-hoc 405 
analysis of data showed that ataluren-treated patients in both populations (ITT and the pre-406 
specified ≥300 to <400 m subgroup) experienced a statistically significant reduction in loss of 407 
clinically meaningful milestones across the 17 NSAA functions versus placebo (both 408 
p=0·010). This finding suggests a broader context of benefit in motor function experienced 409 
by patients receiving ataluren versus those receiving placebo. 410 
 411 
Ataluren was generally well tolerated and no new safety signals were identified. Overall, 412 
efficacy and safety data from this trial demonstrate a favourable risk−benefit profile for 413 
ataluren in patients with nmDMD, particularly when considering the serious, ultimately fatal 414 




LIMITATIONS AND STRENGTHS 417 
The entry criteria employed in this trial were selected to enrich for patients likely to be in 418 
ambulatory decline (patients aged 7−16 years; with a baseline 6MWD ≥150 m and ≤80%-419 
predicted for age and height, and with use of systemic corticosteroids for ≥6 months before 420 
the start of treatment). However, these criteria allowed for inclusion of a broad subset of 421 
study patients with a baseline 6MWD (142·5–526·0 m) and ultimately failed to enrich for 422 
patients in ambulatory decline. Patients with a higher range of ambulatory ability (baseline 423 
6MWD ≥400 m) accounted for 37% of patients in this study. These patients tend to remain 424 
stable in natural history and placebo studies over a 48-week period; and the inclusion of 425 
these patients in the ITT population may have attenuated the treatment effect of ataluren. 426 
More stringent entry criteria with regard to baseline 6MWD subgroups would likely have 427 
increased the overall effect observed, as seen for patients with a baseline 6MWD ≥300 to 428 
<400 m. Owing to the limited sensitivity of the 6MWT (over a 48-week study) in patients with 429 
higher baseline function (6MWD ≥400 m), and because of the increased interpatient 430 
variability seen in patients with lower baseline ambulatory function (6MWD <300 m), an 431 
effect was more likely to be observed in the mid-range subgroup (6MWD ≥300 m to <400 m) 432 
over 48 weeks. In addition, because of the slowly progressive nature of the disorder, a 433 
longer treatment duration is recommended in current regulatory guidelines for DMD,13,14 434 
which were not available when this study was designed. Lastly, the clinical endpoints in this 435 
trial were effort-dependent and/or susceptible to rater bias; efforts to develop objective, non-436 
invasive measures for DMD studies should continue. 437 
 438 
Although the change in 6MWD in the ITT population was not statistically significant, the 439 
benefit observed in patients with a baseline ≥300 to <400 m supports the clinical benefit of 440 
ataluren versus placebo in patients with nmDMD, especially when considering the totality of 441 
supporting evidence. The 48-week data presented here confirm the clinical benefit of 442 




FUTURE RESEARCH DIRECTIONS 445 
Future and ongoing trials should assess the long-term benefits of ataluren in patients with 446 
nmDMD. The delay in loss of ambulation seen with ataluren will hopefully extrapolate to 447 
longer-term benefits in both upper limb and pulmonary function in non-ambulatory patients 448 
with DMD. Future research should therefore determine whether these and other outcome 449 
measures not assessed here, but relevant to non-ambulatory patients, also respond to 450 
treatment with ataluren. The treatment of younger boys (<5 years old) with ataluren would 451 
also be of interest, as treatment initiated earlier is likely to result in the greatest long-term 452 
benefit.14 An additional trial to examine the long-term efficacy and safety of ataluren in 453 
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Table 1: Patient demographics at baseline (as-treated population) 657 




Age, years 9·0 (7–10) 9·0 (8–10) 
Male, n (%) 115 (100%) 115 (100%) 
Race, n (%)   
   Caucasian 89 (77%) 86 (75%) 
   Black 1 (1%) 1 (1%) 
   Asian 7 (6%) 6 (5%) 
   Hispanic 4 (4%) 8 (7%) 
   Other 7 (6%) 4 (4%) 
   Not reported 7 (6%) 10 (9%) 
Height, cm 125·6 (118–132) 126·0 (118–133) 
Weight, kg 29·3 (23–37) 27·0 (24–34) 
Body mass index, kg/m2 18·4 (16–22) 17·9 (16–20) 
Age at diagnosis, years 4·0 (3·3–6·8) 4·0 (2·3–6·9) 
Time from diagnosis to randomisation, years 4·8 (2·2–5·5) 4·7 (2·1–5·9) 
Phenotype diagnosis, n (%)   
   Waddling gait 83 (72%) 76 (66%) 
   Gowers’ manoeuvre 83 (72%) 91 (79%) 
   Calf hypertrophy 91 (79%) 92 (80%) 
6MWD, m 375·2 (314–421) 370·5 (314–422) 
6MWD <300 m, n (%) 25 (22%) 22 (19%) 
6MWD ≥300 to <400 m, n (%) 47 (41%) 52 (45%) 
6MWD ≥400 m, n (%) 43 (37%) 41 (36%) 
Concomitant corticosteroid use   
   Deflazacort 50 (44%) 54 (47%) 
   Prednisone 38 (33%) 37 (32%) 
   Prednisolone 29 (25%) 28 (24%) 
Data are median (25th and 75th percentiles) unless otherwise indicated.6MWD=6-minute 658 
walk distance 659 
  660 
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Table 2: LS mean change from baseline to week 48 (SEM) in time to perform each TFT for ataluren- and placebo-treated patients (ITT 661 
population and a subgroup of patients with a baseline 6MWD ≥300 to <400 m)  662 
 663 
  LS mean change at week 48 (SEM), s     
Group Endpoint Ataluren Placebo LS mean 
difference 
(SEM), s 
p value Combined mean 





10-m run/walk 2·36 (0·60) 3·43 (0·60) −1·1 (0·7) 0·117 6·71 15·9% 
4-stair climb 3·88 (0·66) 5·31 (0·66) −1·4 (0·8) 0·058 6·14 23·3% 
4-stair descend 2·78 (0·69) 4·75 (0·69) −2·0 (0·8) 0·012 4·90 40·2% 
 
≥300 to <400 m 
subgroup 
10-m run/walk 0·92 (0·79) 2·76 (0·76) −1·8 (1·0) 0·066 6·52 28·2% 
4-stair climb 2·27 (0·91) 5·73 (0·88) −3·5 (1·2) 0·003 5·65 61·2% 
4-stair descend 0·54 (0·92) 4·90 (0·89) −4·4 (1·2) <0·001 4·34 100·5% 
P values obtained via ANCOVA with multiple imputation. 664 
*Mean baseline values for time taken to perform each TFT for the total population (ataluren- and placebo-treated patients). 665 
†Difference, % = (LS mean difference/combined mean at baseline) x 100. 666 
6MWD=6-minute walk distance, ANCOVA=analysis of covariance, ITT=intent-to-treat, LS=least square, SEM=standard error of the mean; 667 
TFT=timed function test. 668 
  669 
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Table 3: Reported TEAEs (as-treated population) 670 




Patients with ≥1 TEAE 103 
(89·6%) 
101 (87·8%) 
TEAE by severity†   
Mild‡ 61 (53·0%) 54 (47·0%) 
Moderate‡ 35 (30·4%) 37 (32·2%) 
Severe‡ 7 (6·1%) 9 (7·8%) 
TEAEs by relatedness   
Unrelated 44 (38·3%) 47 (40·9%) 
Unlikely 20 (17·4%) 30 (26·1%) 
Possible 27 (23·5%) 18 (15·7%) 
Probable 12 (10·4%) 6 (5·2%) 
MedDRA system organ class/preferred 
term, 
TEAEs reported for ≥5% of patients 
  
Gastrointestinal disorders 52 (45·2%) 48 (41·7%) 
Vomiting 26 (22·6%) 21 (18·3%) 
Diarrhoea 20 (17·4%) 10 (8·7%) 
Abdominal pain upper 9 (7·8%) 13 (11·3%) 
Nausea 7 (6·1%) 7 (6·1%) 
Constipation 3 (2·6%) 10 (8·7%) 
Abdominal pain 7 (6·1%) 5 (4·3%) 
General disorders and administration 
site conditions 
29 (25·2%) 32 (27·8%) 
Pyrexia 16 (13·9%) 12 (10·4%) 
Disease progression 9 (7·8%) 14 (12·2%) 
Infections and infestations 63 (54·8%) 50 (43·5%) 
Nasopharyngitis 24 (20·9%) 22 (19·1%) 
Upper respiratory tract infection 11 (9·6%) 6 (5·2%) 
Rhinitis 8 (7·0%) 4 (3·5%) 
Injury, poisoning, and procedural complications 35 (30·4%) 34 (29·6%) 
Falls 21 (18·3%) 20 (17·4%) 
Musculoskeletal and connective tissue 
disorders 
32 (27·8%) 32 (27·8%) 
Pain in extremity 10 (8·7%) 14 (12·2%) 
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Back pain 11 (9·6%) 8 (7·0%) 
Nervous system disorders 28 (24·3%) 23 (20·0%) 
Headache 21 (18·3%) 21 (18·3%) 
Respiratory, thoracic, and mediastinal 
disorders 
34 (29·6%) 30 (26·1%) 
Cough 19 (16·5%) 13 (11·3%) 
Oropharyngeal pain 7 (6·1%) 6 (5·2%) 
Patients who had the same adverse event more than once were counted only once for that 671 
adverse event. 672 
†No life-threatening or fatal TEAEs were reported. 673 
‡Mild: sign or symptom not easily tolerated, but not expected to have a clinically significant 674 
effect on the patient’s overall health and well-being, does not interfere with the patient’s 675 
usual functions and is not likely to require medical attention; moderate: sign or symptom 676 
causes interference with usual activity or affects clinical status and may require medical 677 
intervention; severe: sign or symptom is incapacitating or significantly affects clinical status 678 
and likely requires medical intervention and/or close follow-up. 679 
MedDRA=medical dictionary for regulatory activities, TEAE=treatment-emergent adverse 680 
event. 681 
  682 
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FIGURES LEGENDS 683 
Figure 1: Trial profile 684 
Note: Two patients from the as-treated population (one from each treatment arm) were 685 
prematurely discontinued from the study when dystrophin gene sequencing did not confirm 686 
the presence of a nonsense mutation in the dystrophin gene. This meant that they did not 687 
have at least one valid post-baseline 6MWD value, a requirement for the ITT population. 688 
6MWD=6-minute walk distance, ITT=intent-to-treat. 689 
 690 
Figure 2: LS mean change (SEM) from baseline to week 48 in 6MWD for ataluren- and 691 
placebo-treated patients in (A) the ITT population and in (B) the subgroup of patients 692 
with a baseline 6MWD ≥300 to <400 m (pre-specified, mid-range) 693 
ANCOVA model based on change from baseline as the dependent variable, and 694 
independent variables included stratification for age (<9 or ≥9 years old), duration of 695 
previous corticosteroid use (6 to <12 months or ≥12 months) and baseline 6MWD (<350 m 696 
or ≥350 m), treatment, and baseline 6MWD as a covariate.  P values obtained via ANCOVA 697 
via multiple imputations. 698 
6MWD=6-minute walk distance, ANCOVA=analysis of covariance, ITT=intent-to-treat, 699 
LS=least square, SEM=standard error of the mean. 700 
 701 
Figure 3: Percentage of patients who lost the ability to perform each individual item in 702 
the NSAA over 48 weeks (ITT population) 703 
A score of 0 indicated that the patient was unable to perform the function, a score of 1 704 
indicated that the patient performed the function with difficulty (ie, the patient completed the 705 
activity independent of physical assistance from another person using a modified method), 706 
and a score of 2 indicated that the patient performed the function (without modification or 707 




ITT=intent-to-treat, L=Left, NSAA=North Star Ambulatory Assessment, R=Right. 710 
 711 
